Abstract

    Open Access Review Article Article ID: JAMTS-3-121

    How the histamine N-methyltransferase inhibitor metoprine alleviates methamphetamine reward

    Nobue Kitanaka, Junichi Kitanaka*, F Scott Hall, Satoshi Okumura#, Tomoyuki Sakamoto#, George R Uhl and Motohiko Takemura

    Methamphetamine (METH) is a highly addictive psychomotor stimulant drug that is abused worldwide [1].
    METH abuse results in numerous adverse effects after acute administration, as well as an array of adverse outcomes associated with binge use, long-term use, and withdrawal [2- 4]. Acutely METH releases dopamine from synaptic terminals through multiple actions that include inducing reverse transport of dopamine via the dopamine transporter (DAT), impairing the function of the vesicular monoamine transporter-2 (VMAT2), leading to increased cytoplasmic dopamine concentrations,
    and inhibition of monoamine oxidase [5-8]. Moreover, these changes contribute to the production of oxidative metabolites, metabolic impairments, oxidative damage to dopamine terminals, and depletion of tissue dopamine levels [9-11]. METH and related drugs consequently produce broad effects on the central nervous system both acutely and chronically [12-14].

    Keywords: Methamphetamine; Drug addiction; Reward; Histaminergic system; Metoprine; Histamine N-methyltransferase

    Published on: May 12, 2017 Pages: 16-23

    Full Text PDF Full Text HTML DOI: 10.17352/2455-3484.000021
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat

    Indexing/Archiving

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on JAMTS

    Google Reviews 11